Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder |
| May 28, 2018 | May 2018 Bond Updates |
|
PLYMOUTH MEETING, Pa., May 28, 2018 /PRNewswire/ -- Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder (OUD). The resubmission is in... |
| View more at: https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-cam2038-for-opioid-use-disorder-300655354.html |